Stockscreener 앱 받기
77.18
1.32%
-1.03
시간 외 거래:
77.17
-0.01
-0.01%
Edwards Lifesciences Corp 주식(EW)의 최신 뉴스
Edwards Lifesciences’ Quarterly Earnings Preview: What You Need to Know - MSN
Edwards Can't Get Fed. Circ. To Overrule PTAB Amendments - Law360
Edwards Lifesciences Co. (NYSE:EW) Receives Consensus Recommendation of “Hold” from Brokerages - Defense World
Is Edwards Lifesciences Stock Underperforming the Dow? - MSN
Is Edwards Lifesciences Stock Underperforming The Dow? - Barchart.com
Edwards Lifesciences CEO and CFO Set for Exclusive Fireside Chat at Major BofA Healthcare Conference - Stock Titan
DBS Bank Adjusts Price Target on Edwards Lifesciences to $78 From $72, Maintains Hold Rating - MarketScreener
Leerink Partnrs Has Positive Estimate for EW Q3 Earnings - Defense World
Leerink Partners Adjusts PT on Edwards Lifesciences to $83 From $77, Maintains Market Perform Rating - marketscreener.com
Health Care Slips as Sector Continues to Lag Market -- Health Care Roundup - marketscreener.com
Edwards Lifesciences stock rises following competitor’s exit - Investing.com
Edwards Lifesciences’ SWOT analysis: stock poised for growth amid market expansion - Investing.com
Edwards' data shows benefits of early intervention in aortic stenosis - BioWorld MedTech
Edwards’ study demonstrates value in early aortic stenosis intervention - Yahoo Finance
Edwards' New Late-Breaking Data on Severe AS Expected to Boost Stock - Yahoo Finance
Assessing Edwards Lifesciences: Insights From 6 Financial Analysts - Benzinga
Edwards Lifesciences (EW) Receives Price Target Increase from Ci - GuruFocus
Edwards Lifesciences (EW) Receives Price Target Increase from Citigroup | EW Stock News - GuruFocus
Edwards highlights cost savings, improved outcomes with prompt intervention for aortic stenosis - MassDevice
Prompt Intervention for Severe Aortic Stenosis Patients Demonstrates Lower Healthcare Costs, Improved Clinical Outcomes - marketscreener.com
Citigroup Adjusts Price Target on Edwards Lifesciences to $95 From $84, Maintains Buy Rating - marketscreener.com
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | - GuruFocus
Analyst Elevates Edwards Lifesciences (EW) as Top Pick | EW Stoc - GuruFocus
Citi Raises Price Target for Edwards Lifesciences (EW) to $95 | EW Stock News - GuruFocus
Citi adds Edwards Lifesciences stock as Top Pick, drops Insulet - Investing.com
Edwards Lifesciences Holds 2025 EPS Outlook Despite Tariff Headwind - insights.citeline.com
Jim Cramer Notes Edwards Lifesciences (EW) is in a “Good Zone” - Insider Monkey
Edwards Gets FDA Approval for its Next-Generation TAVR Device - Medical Product Outsourcing
Should Edwards Lifesciences Stock Remain in Your Portfolio Now? - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Rating Lowered to Hold at StockNews.com - Defense World
Movers & Shakers: Grant Thornton, United Drug, Edwards Lifesciences, Fine Grain, Viatel, Kepak, EU Commission - Business Post
Intra-annular TAVR valves from Edwards Lifesciences and Abbott deliver similar 1-year outcomes - Cardiovascular Business
Edwards Lifesciences Completes Sale of Critical Care - Quantisnow
Do Wall Street Analysts Like Edwards Lifesciences Stock? - Nasdaq
Edwards Lifesciences (EW) Sees Price Target Increase Amid Regula - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges By Investing.com - Investing.com Canada
Edwards Lifesciences (EW) Sees Price Target Increase by Piper Sa - GuruFocus
Edwards Lifesciences at BofA Conference: Strong Growth Amid Challenges - Investing.com
Piper Sandler Adjusts Price Target on Edwards Lifesciences to $83 From $80, Maintains Overweight Rating - marketscreener.com
Piper Sandler raises Edwards Lifesciences target to $83 - Investing.com
FDA Clears New Indication for Edwards’ Sapien 3 - Orange County Business Journal
Why Edwards Lifesciences (EW) Is Among the Best Medical Device Stocks to Buy Now - Insider Monkey
Edwards Lifesciences Corporation (EW) Announces Amendments to Employee Stock Purchase Plans - GuruFocus
Decoding Edwards Lifesciences Corp (EW): A Strategic SWOT Insigh - GuruFocus
Edwards Lifesciences First Quarter 2025 Earnings: EPS Beats Expectations - Yahoo Finance
Edwards Lifesciences (NYSE:EW) Receives FDA Approval For Groundbreaking TAVR Therapy For Asymptomatic Patients - Yahoo Finance
Edwards Lifesciences Gets FDA Approval for TAVR in Asymptomatic Aortic Stenosis - marketscreener.com
Edwards wins FDA nod for TAVR in aortic stenosis without symptoms - MassDevice
2.54%
4.25%
자본화:
|
볼륨(24시간):